Literature DB >> 8182080

Substitution of an aspartic acid for glycine 700 in the alpha 2(I) chain of type I collagen in a recurrent lethal type II osteogenesis imperfecta dramatically affects the mineralization of bone.

L Cohen-Solal1, L Zylberberg, A Sangalli, M Gomez Lira, M Mottes.   

Abstract

We describe a new dominant mutation of type I collagen responsible for a recurrent lethal osteogenesis imperfecta. Dermal cultured fibroblasts of the proband produced both normal and overmodified type I collagen chains. Previous results (Cohen-Solal, L., Bonaventure, J., and Maroteaux, P. (1991) Hum. Genet. 87, 297-301) and cyanogen bromide peptide mapping after non-equilibrium pH gradient gel electrophoresis indicated that the anomaly was a charge mutation localized in the alpha 2CB3-5A. The mutation was identified as a G to A transition in the COL1A2 gene, which converts glycine 700 to aspartic acid in the alpha 2I chain. This mutation caused the abolition of a ScrFI site, which was also absent in the suspected mosaic father. Pulse-chase experiment showed intracellular retention and increase of the degradation of the synthesized collagen. To understand more directly the tissue defect in osteogenesis imperfecta, skin and especially bone were studied with biochemical and transmission electron microscopy techniques. Collagen matrix of both tissues was dramatically decreased and presented a retarded migration, showing that abnormal molecules were incorporated during the fibrillogenesis. The abnormal collagen mostly remained within the fibroblasts and osteoblasts, which presented typical features of intracellular retention. We observed the presence of spheritic aggregates of mineral, unrelated to the scarce and thin collagen fibrils, in bone. Such abnormal mineralization could be the consequence not only of the decrease of the collagen content but more importantly of the inability of the abnormal molecules to form an organized network necessary to the deposition of apatite crystallites.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8182080

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  Arachnoid cyst and chronic subdural haematoma in a child with osteogenesis imperfecta type III resulting from the substitution of glycine 1006 by alanine in the pro alpha 2(I) chain of type I procollagen.

Authors:  W G Cole; T P Lam
Journal:  J Med Genet       Date:  1996-03       Impact factor: 6.318

2.  A single amino acid substitution (D1441Y) in the carboxyl-terminal propeptide of the proalpha1(I) chain of type I collagen results in a lethal variant of osteogenesis imperfecta with features of dense bone diseases.

Authors:  J M Pace; D Chitayat; M Atkinson; W R Wilcox; U Schwarze; P H Byers
Journal:  J Med Genet       Date:  2002-01       Impact factor: 6.318

Review 3.  Perinatal lethal osteogenesis imperfecta.

Authors:  W G Cole; R Dalgleish
Journal:  J Med Genet       Date:  1995-04       Impact factor: 6.318

4.  Substitutions of aspartic acid for glycine-220 and of arginine for glycine-664 in the triple helix of the pro alpha 1(I) chain of type I procollagen produce lethal osteogenesis imperfecta and disrupt the ability of collagen fibrils to incorporate crystalline hydroxyapatite.

Authors:  A A Culbert; M P Lowe; M Atkinson; P H Byers; G A Wallis; K E Kadler
Journal:  Biochem J       Date:  1995-11-01       Impact factor: 3.857

5.  A novel COL1A1 mutation in a family with osteogenesis imperfecta associated with phenotypic variabilities.

Authors:  Toshiyuki Seto; Toshiyuki Yamamoto; Keiko Shimojima; Haruo Shintaku
Journal:  Hum Genome Var       Date:  2017-03-16

6.  Mutation and polymorphism spectrum in osteogenesis imperfecta type II: implications for genotype-phenotype relationships.

Authors:  Dale L Bodian; Ting-Fung Chan; Annie Poon; Ulrike Schwarze; Kathleen Yang; Peter H Byers; Pui-Yan Kwok; Teri E Klein
Journal:  Hum Mol Genet       Date:  2008-11-07       Impact factor: 6.150

7.  Potential of human fetal chorionic stem cells for the treatment of osteogenesis imperfecta.

Authors:  Gemma N Jones; Dafni Moschidou; Hassan Abdulrazzak; Bhalraj Singh Kalirai; Maximilien Vanleene; Suchaya Osatis; Sandra J Shefelbine; Nicole J Horwood; Massimo Marenzana; Paolo De Coppi; J H Duncan Bassett; Graham R Williams; Nicholas M Fisk; Pascale V Guillot
Journal:  Stem Cells Dev       Date:  2013-10-16       Impact factor: 3.272

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.